ANAC To Report Atopic Dermatitis Trial Results

(RTTNews) - Anacor Pharmaceuticals Inc. (ANAC) is scheduled to report top-line results from its phase III pivotal studies of Crisaborole Topical Ointment 2% for the potential treatment of mild-to-moderate atopic dermatitis in children and adults tomorrow.

The company will host a conference call at 7:30 a.m. ET on Monday, July 13, 2015.

Crisaborole (formerly AN2728) is a novel boron-containing small molecule that inhibits PDE4 and reduces the production of TNF-alpha, a precursor of the inflammation associated with psoriasis, and other cytokines like IL-12 and IL-23, which are believed to be involved in the inflammation process and immune responses.

The phase III trial of Crisaborole was initiated last March, and it consists of two multi-center, double-blind, vehicle-controlled studies which enrolled about 750 subjects per study.

The primary efficacy endpoint is the treatment success at Day 29, defined as an ISGA of "Clear" or "Almost Clear" with at least a 2-grade improvement from baseline. Secondary endpoints are an ISGA of "Clear" or "Almost Clear" at Day 29 as well as time to treatment success.

The ISGA, or Investigator Static Global Assessment, is a 5-point scale from 0 ("clear") to 4 ("severe").

Shares of Anacor have had an impressive rally, gaining more than 170% year-to-date. The stock touched an all-time high of $85.79 on Friday before closing the day's trading at $84.61, up 2.36%.

Are you following ANAC?

If so, what do you think the outcome of the trial will be - Positive or Negative?

Will the stock rally continue, stall or reverse?

Let us know in the comments section.